Albert David Limited (ALBERTDAVD.NS)
INR 851.7
(0.7%)
INR 851.7
(0.7%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.04 Billion INR | -21.53% |
| 2022 | 598.67 Million INR | 32.17% |
| 2021 | 567.75 Million INR | 95.97% |
| 2020 | 364.59 Million INR | -43.05% |
| 2019 | 376.13 Million INR | 16.89% |
| 2018 | 366.9 Million INR | 43.36% |
| 2017 | 307.81 Million INR | -14.63% |
| 2016 | 356.52 Million INR | -13.78% |
| 2015 | 740.7 Million INR | -14.26% |
| 2014 | 386.75 Million INR | 16.85% |
| 2013 | 334.19 Million INR | 21.0% |
| 2012 | 272.52 Million INR | 12.98% |
| 2011 | 236.66 Million INR | -17.49% |
| 2010 | 290.19 Million INR | 1.25% |
| 2009 | 285.99 Million INR | 13.41% |
| 2008 | 248.23 Million INR | 12.36% |
| 2007 | 220.63 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 8.78 Million INR | 19.63% |
| 2023 Q3 | 252.37 Million INR | -10.07% |
| 2023 Q4 | 95.69 Million INR | -62.08% |
| 2023 Q1 | 311.19 Million INR | 224.07% |
| 2023 Q2 | 280.63 Million INR | -9.82% |
| 2023 FY | - INR | -21.53% |
| 2022 Q1 | 154.33 Million INR | 831.88% |
| 2022 FY | - INR | 32.17% |
| 2022 Q2 | 277.77 Million INR | 79.99% |
| 2022 Q4 | 96.02 Million INR | -39.01% |
| 2022 Q3 | 157.44 Million INR | -43.32% |
| 2021 Q2 | 186.27 Million INR | 21.04% |
| 2021 Q4 | -21.08 Million INR | -115.87% |
| 2021 FY | - INR | 95.97% |
| 2021 Q1 | 153.9 Million INR | 803.77% |
| 2021 Q3 | 132.89 Million INR | -28.66% |
| 2020 Q3 | 66.32 Million INR | -53.47% |
| 2020 Q2 | 142.53 Million INR | 3487.52% |
| 2020 Q1 | 3.97 Million INR | -75.61% |
| 2020 FY | - INR | -43.05% |
| 2020 Q4 | -21.86 Million INR | -132.97% |
| 2019 Q4 | 16.29 Million INR | -83.16% |
| 2019 FY | - INR | 16.89% |
| 2019 Q1 | 152.04 Million INR | 32.98% |
| 2019 Q2 | 139.93 Million INR | -7.96% |
| 2019 Q3 | 96.73 Million INR | -30.87% |
| 2018 Q2 | 35.53 Million INR | -74.15% |
| 2018 Q4 | 114.33 Million INR | 94.67% |
| 2018 FY | - INR | 43.36% |
| 2018 Q1 | 137.48 Million INR | -10.39% |
| 2018 Q3 | 58.73 Million INR | 65.29% |
| 2017 Q2 | 153.55 Million INR | 255.14% |
| 2017 FY | - INR | -14.63% |
| 2017 Q4 | 153.42 Million INR | 70.64% |
| 2017 Q3 | 89.91 Million INR | -41.45% |
| 2017 Q1 | -98.98 Million INR | -204.48% |
| 2016 Q3 | 1.22 Million INR | -99.04% |
| 2016 FY | - INR | -13.78% |
| 2016 Q1 | 66.58 Million INR | -14.72% |
| 2016 Q2 | 127.69 Million INR | 91.78% |
| 2016 Q4 | 94.73 Million INR | 7652.54% |
| 2015 Q3 | 40.1 Million INR | -70.02% |
| 2015 FY | - INR | -14.26% |
| 2015 Q1 | 78.28 Million INR | -25.15% |
| 2015 Q2 | 133.74 Million INR | 70.85% |
| 2015 Q4 | 78.07 Million INR | 94.7% |
| 2014 Q3 | 54.93 Million INR | -62.08% |
| 2014 Q4 | 104.58 Million INR | 90.36% |
| 2014 Q2 | 144.88 Million INR | 84.42% |
| 2014 Q1 | 78.56 Million INR | -34.27% |
| 2014 FY | - INR | 16.85% |
| 2013 Q3 | 19.06 Million INR | -84.65% |
| 2013 Q4 | 119.52 Million INR | 527.02% |
| 2013 Q1 | 64.91 Million INR | -33.63% |
| 2013 FY | - INR | 21.0% |
| 2013 Q2 | 124.22 Million INR | 91.36% |
| 2012 Q1 | 56.26 Million INR | -44.05% |
| 2012 FY | - INR | 12.98% |
| 2012 Q4 | 97.81 Million INR | 2688.3% |
| 2012 Q3 | -3.77 Million INR | -103.13% |
| 2012 Q2 | 120.55 Million INR | 114.28% |
| 2011 Q4 | 100.56 Million INR | 4324.2% |
| 2011 FY | - INR | -17.49% |
| 2011 Q2 | 94.89 Million INR | 0.0% |
| 2011 Q3 | 2.27 Million INR | -97.6% |
| 2010 FY | - INR | 1.25% |
| 2009 FY | - INR | 13.41% |
| 2008 FY | - INR | 12.36% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Hester Biosciences Limited | 539.47 Million INR | -93.787% |
| Alembic Limited | 1.11 Billion INR | 6.353% |
| Alkem Laboratories Limited | 24.19 Billion INR | 95.679% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 89.129% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -812.372% |
| Bajaj HealthCare Limited | 406.23 Million INR | -157.342% |
| FDC Limited | 3.38 Billion INR | 69.119% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 84.767% |
| Gufic Biosciences Limited | 1.48 Billion INR | 29.386% |
| Hikal Limited | 2.69 Billion INR | 61.169% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 84.764% |
| Ind-Swift Limited | 1.06 Billion INR | 1.844% |
| Innova Captab Limited | 1.66 Billion INR | 37.336% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -223.2% |
| Jubilant Pharmova Limited | 8 Billion INR | 86.942% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -263.72% |
| Laurus Labs Limited | 8 Billion INR | 86.942% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | 22.176% |
| Lupin Limited | 36.96 Billion INR | 97.172% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -497.569% |
| Medico Remedies Limited | 129.09 Million INR | -709.815% |
| Morepen Laboratories Limited | 1.72 Billion INR | 39.429% |
| Nectar Lifesciences Limited | 1.53 Billion INR | 31.92% |
| Orchid Pharma Limited | 1.41 Billion INR | 26.336% |
| Procter & Gamble Health Limited | 3.07 Billion INR | 65.996% |
| RPG Life Sciences Limited | 1.28 Billion INR | 18.422% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 137.047% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 99.244% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 77.648% |
| Themis Medicare Limited | 562.6 Million INR | -85.818% |
| Unichem Laboratories Limited | 742.35 Million INR | -40.825% |
| Vaishali Pharma Limited | 31.71 Million INR | -3196.72% |
| Venus Remedies Limited | 711.8 Million INR | -46.87% |
| Wanbury Limited | 985.49 Million INR | -6.082% |
| Windlas Biotech Limited | 781.72 Million INR | -33.734% |
| ZIM Laboratories Limited | 462.09 Million INR | -126.235% |
| Ipca Laboratories Limited | 13.29 Billion INR | 92.139% |
| Aarti Drugs Limited | 3.24 Billion INR | 67.82% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 73.259% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -7944.191% |
| Brooks Laboratories Limited | 41.72 Million INR | -2405.327% |
| Eris Lifesciences Limited | 6.98 Billion INR | 85.036% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 59.893% |
| Sigachi Industries Limited | 883.39 Million INR | -18.341% |
| Sakar Healthcare Limited | 393.26 Million INR | -165.83% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 98.308% |
| Divi's Laboratories Limited | 25.43 Billion INR | 95.889% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 55.642% |
| Mankind Pharma Limited | 28.09 Billion INR | 96.279% |
| Sequent Scientific Limited | 549.8 Million INR | -90.146% |
| Neuland Laboratories Limited | 4.74 Billion INR | 77.983% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 88.801% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 90.784% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 98.141% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -53.379% |
| Wockhardt Limited | 1.08 Billion INR | 3.202% |
| Bal Pharma Limited | 345.59 Million INR | -202.502% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.816% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | 29.317% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -358.169% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | 83.094% |
| Shilpa Medicare Limited | 2.58 Billion INR | 59.605% |
| Valiant Laboratories Limited | 12.73 Million INR | -8106.476% |
| Ajanta Pharma Limited | 12.56 Billion INR | 91.68% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -2214.675% |
| Granules India Limited | 8.6 Billion INR | 87.849% |
| Medicamen Biotech Limited | 245.66 Million INR | -325.557% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -142.966% |
| Piramal Enterprises Limited | -3.86 Billion INR | 127.076% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 97.014% |
| NATCO Pharma Limited | 18.79 Billion INR | 94.438% |
| Suven Life Sciences Limited | -992.78 Million INR | 205.303% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1363.702% |
| Strides Pharma Science Limited | 3.76 Billion INR | 72.231% |
| Indoco Remedies Limited | 2.64 Billion INR | 60.506% |
| Alpa Laboratories Limited | 229.96 Million INR | -354.609% |
| Lasa Supergenerics Limited | -65.08 Million INR | 1706.366% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 128.016% |